Showing results (231-240 of 352) with videos related to
Sort By:
Pageof 36
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.American Journal of Clinical Dermatology|September 30, 2018
Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Sanminder Singh, Robert E Kalb, Elke M G J de Jong, et al.Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.Digestive Diseases and Sciences|May 29, 2024
The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn's DiseaseJud C Janak, Anita M Loughlin, Page C Moore, et al.Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.Journal of Drugs in Dermatology : JDD|August 7, 2025
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis PatientsBruce E Strober, Jud C Janak, Timothy Fitzgerald, et al.Acta Dermato-Venereologica|September 12, 2024
Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician SurveyBrian S Kim, Sonja Ständer, Kenji Kabashima, et al.The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.Pageof 36